1. At a Glance
Solara Active Pharma Sciences Ltd, a pure-play API manufacturer, has gone from glory to gory and back (sort of). After a hellish FY24 with a ₹567 Cr loss, FY25 sees a faint heartbeat—₹1 Cr net profit. Is it a turnaround or just CPR before another flatline?
2. Introduction with Hook
Imagine you’re in an ambulance. Sirens blaring. Vital signs dropping. That was Solara in FY24—minus ₹567 Cr in losses, negative margins, shareholder erosion, and pledges galore.
Then in FY25, a miracle. The patient blinks. Whispers: “₹206 Cr EBITDA.”
- FY24 Net Loss: ₹567 Cr
- FY25 Net Profit: ₹1 Cr
- FY25 OPM: 16% (from -7% in FY24)
- Debt reduced by ₹216 Cr
- Rights issue: ₹449 Cr raised
Still skeptical? Yeah, us too.
3. Business Model (WTF Do They Even Do?)
Solara is all about APIs—Active Pharmaceutical Ingredients. No fancy pills, just the core molecules that make them tick.
Segments:
- 60+ commercial APIs
- 73+ countries
- Focus: Anti-infectives, anthelmintics, malaria, analgesics
- CDMO services (contract manufacturing)
Dependence Warning: Top 10 molecules = 84% of revenues. If even one slips—RIP margins.
USP? Regulatory clearances, scale in legacy
